HRP20150552T1 - Metoda za sprjeäśavanje razvoja reumatoidnog artritisa kod podložnih osoba s nediferenciranim artritisom - Google Patents

Metoda za sprjeäśavanje razvoja reumatoidnog artritisa kod podložnih osoba s nediferenciranim artritisom Download PDF

Info

Publication number
HRP20150552T1
HRP20150552T1 HRP20150552TT HRP20150552T HRP20150552T1 HR P20150552 T1 HRP20150552 T1 HR P20150552T1 HR P20150552T T HRP20150552T T HR P20150552TT HR P20150552 T HRP20150552 T HR P20150552T HR P20150552 T1 HRP20150552 T1 HR P20150552T1
Authority
HR
Croatia
Prior art keywords
molecule
use according
ctla4
immunoglobulin
amino acid
Prior art date
Application number
HRP20150552TT
Other languages
English (en)
Croatian (hr)
Inventor
George Vratsanos
Jean-Claude Becker
Michael Corbo
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41264941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20150552(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20150552T1 publication Critical patent/HRP20150552T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
HRP20150552TT 2008-05-05 2009-05-05 Metoda za sprjeäśavanje razvoja reumatoidnog artritisa kod podložnih osoba s nediferenciranim artritisom HRP20150552T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5033608P 2008-05-05 2008-05-05
US12/387,359 US7915222B2 (en) 2008-05-05 2009-05-01 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
PCT/US2009/042761 WO2009137424A1 (en) 2008-05-05 2009-05-05 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
EP20090743410 EP2279206B1 (en) 2008-05-05 2009-05-05 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Publications (1)

Publication Number Publication Date
HRP20150552T1 true HRP20150552T1 (hr) 2015-06-19

Family

ID=41264941

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150552TT HRP20150552T1 (hr) 2008-05-05 2009-05-05 Metoda za sprjeäśavanje razvoja reumatoidnog artritisa kod podložnih osoba s nediferenciranim artritisom

Country Status (25)

Country Link
US (3) US7915222B2 (enExample)
EP (2) EP2279206B1 (enExample)
JP (1) JP2011522795A (enExample)
KR (1) KR20110014180A (enExample)
CN (1) CN102037010A (enExample)
AR (1) AR071672A1 (enExample)
AU (1) AU2009244448B2 (enExample)
BR (1) BRPI0912249A2 (enExample)
CA (1) CA2723698C (enExample)
CL (1) CL2009001082A1 (enExample)
DK (1) DK2279206T3 (enExample)
EA (1) EA201001749A1 (enExample)
ES (1) ES2539840T3 (enExample)
HK (1) HK1208230A1 (enExample)
HR (1) HRP20150552T1 (enExample)
HU (1) HUE025256T2 (enExample)
IL (1) IL208691A (enExample)
MX (1) MX2010011503A (enExample)
NZ (1) NZ589020A (enExample)
PL (1) PL2279206T3 (enExample)
PT (1) PT2279206E (enExample)
SI (1) SI2279206T1 (enExample)
TW (2) TWI454278B (enExample)
WO (1) WO2009137424A1 (enExample)
ZA (1) ZA201007914B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
CA2851322C (en) * 2011-10-10 2020-03-31 Medimmune Limited Treatment for rheumatoid arthritis with gm csfr alpha antibodies
US20140006055A1 (en) * 2012-06-27 2014-01-02 Iagnosis, Inc. Integrated Medical Evaluation and Record Keeping System
US20150232558A1 (en) * 2012-10-30 2015-08-20 Emory University Stimulating bone formation by inhibition of cd28 co-stimulation
WO2014151230A2 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
US20170042972A1 (en) * 2014-04-25 2017-02-16 Chetan KARYEKAR Use of ctla4 compound for achieving drug-free remission in subjects with early ra
CN121159719A (zh) 2015-04-17 2025-12-19 高山免疫科学股份有限公司 具有可调的亲和力的免疫调节蛋白
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN110148465B (zh) * 2019-05-10 2023-07-04 中山大学孙逸仙纪念医院 一种用于分析类风湿性关节炎的系统
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070776B1 (en) 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
CA2580812A1 (en) 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctla4 receptor, fusion proteins containing it and uses thereof
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
CA2154487A1 (en) * 1993-01-21 1994-08-04 Nicholas S. Hill Vaccines and methods for preventing and treating fescue toxicosis in herbivores
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
EP0892643B2 (en) 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MXPA02012157A (es) 2000-06-09 2003-06-06 Bristol Myers Squibb Co Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos.
EP1935427B1 (en) * 2000-07-03 2018-03-07 Bristol-Myers Squibb Company Uses of soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2436139A1 (en) 2001-01-26 2002-08-01 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
MXPA05006522A (es) 2002-12-23 2006-02-17 Bristol Myers Squibb Co Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
MXPA05006523A (es) 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
SG144925A1 (en) 2003-08-04 2008-08-28 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble ctla4 molecule
US7930013B2 (en) 2005-06-29 2011-04-19 Compumedics Limited Sensor assembly with conductive bridge
EP1933777B1 (en) * 2005-08-22 2017-06-14 Incept, LLC Flared stents and apparatus for using them
US8476239B2 (en) 2005-12-20 2013-07-02 Bristol-Myers Squibb Company Stable protein formulations
DK1969007T3 (da) 2005-12-20 2013-11-25 Bristol Myers Squibb Co Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
US7528111B2 (en) 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Also Published As

Publication number Publication date
PT2279206E (pt) 2015-07-27
AR071672A1 (es) 2010-07-07
NZ589020A (en) 2012-05-25
CA2723698A1 (en) 2009-11-12
DK2279206T3 (en) 2015-07-27
IL208691A0 (en) 2010-12-30
AU2009244448A1 (en) 2009-11-12
PL2279206T3 (pl) 2015-09-30
WO2009137424A1 (en) 2009-11-12
CA2723698C (en) 2018-03-06
EP2279206B1 (en) 2015-04-22
US7915222B2 (en) 2011-03-29
CN102037010A (zh) 2011-04-27
TW201444575A (zh) 2014-12-01
US20090280119A1 (en) 2009-11-12
TWI454278B (zh) 2014-10-01
JP2011522795A (ja) 2011-08-04
US9012408B2 (en) 2015-04-21
EP2279206A1 (en) 2011-02-02
IL208691A (en) 2015-01-29
EA201001749A1 (ru) 2011-06-30
CL2009001082A1 (es) 2010-02-12
EP2279206A4 (en) 2011-05-25
AU2009244448B2 (en) 2014-07-31
US20130195865A1 (en) 2013-08-01
ZA201007914B (en) 2011-07-27
EP2891665A1 (en) 2015-07-08
SI2279206T1 (sl) 2015-08-31
HUE025256T2 (en) 2016-02-29
HK1208230A1 (en) 2016-02-26
BRPI0912249A2 (pt) 2015-10-20
ES2539840T3 (es) 2015-07-06
TW200948381A (en) 2009-12-01
MX2010011503A (es) 2010-11-09
HK1148291A1 (en) 2011-09-02
US20110142835A1 (en) 2011-06-16
KR20110014180A (ko) 2011-02-10
US8435952B2 (en) 2013-05-07

Similar Documents

Publication Publication Date Title
HRP20150552T1 (hr) Metoda za sprjeäśavanje razvoja reumatoidnog artritisa kod podložnih osoba s nediferenciranim artritisom
JP2011522795A5 (enExample)
Tzartos et al. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera.
Loo et al. Identification of residues in the drug translocation pathway of the human multidrug resistance P-glycoprotein by arginine mutagenesis
Buckley et al. Age impairs sit-to-walk motor performance
HRP20211081T1 (hr) Anti-pro/latentna miostatinska protutijela i njihove uporabe
JP2019507589A5 (enExample)
JP2010529957A5 (enExample)
PE20190743A1 (es) Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib
HRP20141111T1 (hr) Sastav her2-protutijela
HRP20240676T1 (hr) Proteini domena skele na bazi fibronektina koji vezuju miostatin
JP2014221758A5 (enExample)
HRP20231645T1 (hr) T stanični receptori
ES2724364T3 (es) Procedimiento de tratamiento de fibrosis pulmonar idiopática
BRPI0821266B8 (pt) Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica
CN110914294A (zh) 重组卵泡抑素-fc融合蛋白及其在治疗杜氏肌营养不良中的用途
Rist et al. Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full agonist at the human Y2 receptor
Mâaref et al. Kinematics in the terminal swing phase of unilateral transfemoral amputees: microprocessor-controlled versus swing-phase control prosthetic knees
KR20060065588A (ko) 면역 조절 활성, 항염증 활성 및 항바이러스 활성을 지니는펩티드 및 펩티도미메틱
EA201290028A1 (ru) Однодоменные антитела против рецептора tgf-бета ii типа
Van Criekinge et al. Age-and sex-related differences in trunk kinematics during walking in able-bodied adults
JP2019506408A5 (enExample)
Salas et al. Ossified meniscus and cyamo-fabella in some fossil sloths: A morpho-functional interpretation
Garavaglia et al. Two single cases treated by a new pseudoelastic upper-limb orthosis for secondary dystonia of the young
EP1653988A2 (en) Leukocyte internalized peptide-drug conjugates